

CURRICULUM VITAE
SHAO-CHUN WANG (王紹椿), Ph.D.

ADDRESS China Medical University Hospital
Cancer Center Building, 9th Floor
Center for Molecular Medicine
No.6 Hsueh-Shih Road
Taichung City, Taiwan, R.O.C. 404
Tel: +011-886-4-22052121 ext. 7921

Present position

Professor and Co-Director, Graduate Institute of Biomedical Sciences (GIBS)
Investigator and Deputy Director, Center for Molecular Medicine
China Medical University College of Medicine and Hospital
Taiwan, R.O.C.

Adjunct Associate Professor
Department of Cancer Biology
University of Cincinnati College of Medicine
Cincinnati, Ohio USA

Adjunct Professor
Department of Biotechnology
Asia University
Taiwan, R.O.C.

Office Address:

2. EDUCATION

07/1984-07/1988 B.Sc. - Pharmacy, Taipei College of Medicine, Taipei, Taiwan
09/1988-07/1990 Military Service (Second Lieutenant of Air Force, Taiwan R.O.C.)
09/1990-12/1995 Ph.D. - Genetics and Cell Biology, University of Minnesota Twin Cities, Minnesota, USA (Mentor: Dr. Peter Lefebvre)
01/1996-03/1998 Post-doctoral fellow - tumor biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas USA (Mentor: Dr. Mien-Chie Hung)

3. ACADEMIC APPOINTMENTS

04/01/1998-05/01/2000 Research Associate - Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas USA (Mentor: Dr. Mien-Chie Hung)
05/02/2000-01/31/2002 Instructor, University of Texas M. D. Anderson Cancer Center, Department of Molecular and Cellular Oncology, Houston, Texas (Mentor: Dr. Mien-Chie Hung)
02/01/2002-02/28/2007 Research-track Assistant Professor, University of Texas M. D. Anderson Cancer Center, Department of Molecular and Cellular Oncology, Houston, Texas (Mentor: Dr. Mien-Chie Hung)
2007/03-2008/08 Assistant Professor, Department of Surgery, University of Cincinnati College of Medicine, Ohio
2008/09-2014/08 Assistant Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio (formerly the Department of Cancer and Cell Biology)
2007-present Faculty, Cancer and Cell Biology Graduate Program; University of Cincinnati College of Medicine, Ohio

2007-present Associate Member, University of Cincinnati Cancer Center, Ohio
 2011-present Member, Center for Clinical and Translational Science and Training (CCTST), University of Cincinnati, Ohio
 2013-present Member, Cincinnati Cancer Center (CCC)
 2013-present Member, University of Cincinnati Cancer Institute (UCCI)
 09/2014-01/2016 Associate Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio
 01/2016-present Adjunct Associate Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio
 01/15/2016-present Full Research Fellow, Center of Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
 01/15/2016-present Deputy Director, Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
 03/30/2016-present Professor, School of Medicine, China Medical University, Taichung, Taiwan
 08/01/2016-present Co-Director, Institute of Biomedical Sciences, China Medical University, Taiwan
 08/01/2016-present Program Director, CMU-Academia Sinica Graduate Program of Biomedical Sciences, China Medical University, Taiwan
 08/01/2016-present Program Director, CMU-Academia Sinica Graduate Program of Translational Medicine, China Medical University, Taiwan
 08/01/2016-present Program Director, Minister of Education PhD program of biomedical technology and industry.

4. MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

1999-present Member, American Association of Cancer Research (AACR)
 2012-present Member, American Heart Association (AHA)
 2015-present Life Member, Society of Chinese Bioscientists in America (SCBA)

5. SERVICE

A. Institutional:

2007 Grant proposal review panel, Ride Cincinnati Pilot Program
 2007 Grant proposal review panel, UC Cancer Center Pilot Program
 2007 Interview of Chair and faculty recruitments (Surgery)
 2007-present Interview of Chair and faculty recruitments (Cancer and Cell Biology, Environmental Health)
 2007, 2012-present Grant proposal review panel, University Research Council
 2008-present Interviewing graduate candidates and recruitment activities of the cancer and cell biology graduate program
 2007-present Judge of the Graduate Student Research Forum (GSRF)
 2007-present Judge of the Capstone Symposium
 2008-2009, 2012 Selection committee/research host of finalists, ROSE early acceptance to medical school program
 2009-present Judge for the Student Symposium of Cancer and Cell Biology
 2009-2014 Director, Cancer and Cell Biology Seminar Series
 2011-2015 Cardell Fellowship for Excellence in Graduate Research Selection Committee
 2012 Grant proposal review panel, Center for Environmental Genetics Pilot Project Program (CEG-PPP)
 2013-present Breast Cancer Center of Excellence Basic Science Research Committee
 2013-present Cancer and Cell Biology Graduate Program Recruitment Committee
 05/04/2016 China Medical University graduate program interview committee (PhD Program of Biological Technology Industry)

06/23/2016	China Medical University, College of Medicine, CMU-MDACC PhD student training program recruitment/selection committee
06/29/2016	Host of delegation visitors from University of Missouri College of Engineering
07/01/2016	Session Co-Chair - International symposium on biomedical sciences July 1-2, 2016, China Medical University; Taichung, Taiwan
08/30/2016-08/31/2016	Brainstorm retreat invited by the Minister of Science and Technology (MOST) on Innovative translational research: novel targets in human health and disease
09/09/2016	Selection Committee of Outstanding PhD student Award of College of Medicine, China Medical University
09/29/2016	China Medical University, College of Medicine, CMU-MDACC student training program recruitment/selection committee
09/2016-present	Member of the Cancer Center of Excellence program for the Summit University in Taiwan
10/07/2016	Committee Chair, CMU-MDACC student training program recruitment/selection committee, China Medical University, College of Medicine
11/11/2016	Host of international guest (Dr. Jun-Lin Guan, Professor and Endowed Chair, Department of Cancer Biology, University of Cincinnati) (supported by CMU/CMUH and the Global Networking Talent Plan, Ministry of Education, Taiwan, R.O.C.)
12/09/2016	Session Chair of 2016 CMU-UCI (University of California Irvine) Joint Symposium, China Medical University
01/04/2017	China Medical University graduate program selection committee (Program of Biomedical Technology & Industry)
08/01/2016-07/31/2017	China Medical University Committee of Graduate Education
08/01/2016-07/31/2017	China Medical University Committee of Academy Ethics
02/24/2017	China Medical University PhD graduate program interview committee (Program of Health Technology Industry)
03/25/2017	China Medical University medical student interviewing committee (Star Program; Department of Medicine)
05/25/2017	China Medical University graduate program selection committee (MD-PhD program)

B. External:

Ad hoc Grant Review – Regional and National (Taiwan):

2016 Ministry of Science and Technology (MOST) Department of Life Science, Taiwan (primary review panel)

2017 Ministry of Science and Technology (MOST) Department of Life Science, Taiwan (study section panel of Biochemistry & Molecular Biology)

2017 Ministry of Science and Technology (MOST) Department of Life Science, Taiwan (review committee - Innovative Translational Research: Novel Targets in Human Health and Diseases)

Ad hoc Grant Review – Regional and National (US):

2007-2008 University of Texas M. D. Anderson Cancer Center Breast SPORE project applications

2010-2013 Florida Department of Health Biomedical Research Programs/James and Esther King Biomedical Research Program

2013-2015 American Heart Association (AHA) grant review study section (Molecular Signaling Committee)

2013-present American Heart Association (AHA) Council on Basic Cardiovascular Sciences

2013-present NIH Early Career Reviewer (ECR) program of Center for Scientific Review (CSR)

Ad hoc Grant Review – International:

2008-2009	National Research Program for Genomic Medicine (NPRGM) of the National Science Council (Taiwan)
2008-present	Research Grant Council (Hong Kong)
2012	Academic Sinica Thematic Research Program (Taiwan)
2013	National Science Centre (Poland)
2014	Genesis Oncology Trust (New Zealand)

Ad hoc Manuscript Review:

American Journal of Pathology, Archivum Immunologiae et Therapiae Experimentalis, Biomolecules, BMC Cancer, Breast Cancer Research, British Journal of Pharmacology, Cancer Letter, Cancer Research, Cancer Research Frontier, Current Cancer Drug Targets, Endocrine-related Cancer, Expert Opinion on Drug Safety, Frontiers, International Journal of Cancer, International journal of Molecular Sciences, Journal of Biomedical Research, Journal of Cell Biology, Journal of Clinical Investigation, Journal of Oncology and Biomarker Research, Journal of Nature and Science (JNSCI), Journal of Pathology, Journal of visualized Experiments (JoVE), Molecular Cancer, Molecular Cancer Therapeutics, Molecular Carcinogenesis, Molecular Therapy, Oncogene, Oncotarget, PLOS ONE, Toxicological Sciences, Stem Cells.

Editorial Board Member:

- 1) Journal of Cancer Biology and Research. Term started in June 2013.
- 2) Journal of Oncology and Biomarker Research. Term started in December 2013.
- 3) International Journal of Cancer Research and Molecular Mechanisms. Term started in October 2014.
- 4) BioMed Research International - Special Issue: Emerging agents against inflammation-related diseases: mechanisms and therapies, 2014. (as a consulting member)
- 5) Frontiers in Oncology Review Editor Board. Term started on Oct. 19, 2015

6. HONORS

1996-1997	Breast Cancer Research Project Award; University of Texas, M. D. Anderson Cancer Center.
1999-2000	W. M. Keck Center for Cancer Gene Therapy Development Awards for the Human Cancer Gene Prevention and Therapy Program; University of Texas, M. D. Anderson Cancer Center.
2000-2002	Susan G. Komen Breast Cancer Foundation Translational Research Award (BCTR 2000693).
2003-2007	American Cancer Society Research Scholar Grant (RSG-03-138-01-CCD 01) (Co-PI).
2007-2008	University of Cincinnati Cancer Center Research Award
2012-2013	University of Cincinnati Provost's Pilot Research Award
2013	University of Cincinnati College of Medicine Internal Study Section Award for meritorious grant proposal
2013-present	NIH Early Career Reviewer (ECR) program of Center for Scientific Review (CSR)
2014-2015	Cincinnati Cancer Center Affinity Pilot Research Award
2015-2016	Marlene Harris Ride Cincinnati Breast Cancer Research Award
2016-present	Scholar of Global Networking Talent Plan, Ministry of Education, Taiwan R.O.C.

7. PUBLICATIONS:

1. Hunt, B., Wang, Y.-L., Chen, M.-S., **Wang, S.-C.***, Waltz, S.* Maternal diethylhexyl phthalate exposure affects adiposity and insulin tolerance in offspring in a PCNA-dependent manner. *Environmental Research*, 159: 588-594, 2017. (*, co-corresponding authors)

2. De Toni, E.N., Ziesch, A., Rizzani, A., Török, H.-P., Hocke, S., Lü, S., **Wang, S.-C.**, Hucl, T., Göke, B., Bruns, C., Gallmeier, E. Inactivation of *BRCA2* in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis. *Oncotarget*, 7(8):9477-9490, 2016.
3. Broering, T.J., Wang, Y.-L., Pandey, R.N., Hegde, R.S., **Wang, S.-C.**, Namekawa, S.H. BAZ1B is dispensable for H2AX phosphorylation on Tyrosine 142 during spermatogenesis. *Biology Open*, 4(7):873-884, 2015.
4. Wang, Y.-L., Overstreet, AM, Chen, M.-S., Wang, J., Zhao, H., Ho, P.-C., Molly, S., **Wang, S.-C.*** Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of *HOTAIR*. *Oncotarget* 6(13), 11150-11161, 2015
5. Hsieh, T.-H., Hsu, C.-Y., Tsai, C.-F., Long, C.-Y., Chai, C.-Y., Hou, M.-F., Lee, J.-N., **Wang, S.-C.**, and Tsai, E.-M. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. *Oncotarget* 6(1), 494-509, 2015.
6. **Wang, S.-C.*** PCNA – a ubiquitous house keeper or a potential therapeutic target? *Trend in Pharmacological Sciences (TIPS)* 35, 178-186, 2014.
7. Zhao H., Chen, M.-S., Lo, Y.-H., Waltz, S.E., Wang, J., Ho, P.C., Vasiliauskas, J., Plattner, R., Wang, Y.-L., **Wang, S.-C.*** The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. *Oncogene* 33, 1429-1437, 2014.
8. Lo, Y.-H., Ho, P.-C., Chen, M.-S., Hugo, E., Ben-Jonathan, N., **Wang, S.-C.*** Phosphorylation at tyrosine 114 of Proliferating Cell Nuclear Antigen (PCNA) is required for adipogenesis in response to high fat diet. *Biochem. Biophys. Res. Commun.* 430, 43-48, 2013.
9. Yu, Y.-L., Chou, R.-H., Liang, J.-H., Chang, W.-J., Su, K. -J., Tseng, Y.- J., Huang, W.-C., **Wang, S.-C.**, Hung, M.-C. Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides. *PLoS ONE* 8(4): e61362, 2013.
10. Cui, J., Germer, K., Wu, T., Wang, J., Luo, J., **Wang, S.-C.**, Wang, Q., Zhang, X. Crosstalk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. *Cancer Research* 72, 5625-5634, 2012.
11. Hsieh, T.H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., His, E., Suen, J.-L., Hung, C.-H., Lee, J.-N., Chai, C.-Y., **Wang, S.-C.**, Tsai, E.-M. n-Butyl benzyl phthalate promotes breast cancer progression by inducing expression of lymphoid enhancer factor 1. *PLoS ONE* 7:e42750, 2012.
12. Lo, Y.-H., Ho, P.-C., **Wang, S.-C.*** Epidermal growth factor receptor (EGFR) protects proliferating cell nuclear antigen (PCNA) from cullin 4a (CUL4A)-mediated proteolysis. *Journal of Biological Chemistry* 287, 27148-27157, 2012. PMC3411057
13. Zhao, H., Lo, Y.-H., Ho, P.-H., Bedford, M.T., Hung, M.-C., and **Wang, S.-C.*** Interaction of proliferation cell nuclear antigen (PCNA) with the non-receptor tyrosine kinase c-Abl in cell proliferation and response to DNA damages in breast cancer cells. *PLoS ONE* 7(1): e29416. doi:10.1371/journal.pone.0029416, 2012. PMC3251568.
14. Hsieh, T.-H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., Lee, J.-N., Chai, C.-Y., **Wang, S.-C.***, Tsai, E.-M.* Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. (*, co-corresponding authors) *Journal of the Federation of American Societies for Experimental Biology (FASEB J)* 26:778-787, 2012
15. Ding, Q, Chang, C.-J., Xie, X., Xia, W., Yang, J.-Y., **Wang, S.-C.**, Wang, Y., Xia, J., Chen, L., Cai, C., Li, H., Yen, C.-J., Kuo, H.-P., Lee, D.-F., Lang, J., Huo, L., Cheng, X., Chen, Y.-J., Li, C.-W., Jeng, L.-B., Hsu, J.-L., Li, L.-Y., Tan, A., Curley, S.A., Ellis, L.M., DuBois, R.N., Hung, M.-C. APOBEC3G promotes liver metastasis in orthotopic colorectal cancer mouse model and predicts human hepatic metastasis. *Journal of Clinical Investigation* 121:4526-4536, 2011.
16. Lo, Y.-H., Ho, P.-C., Zhao, H., and **Wang, S.-C.*** Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). *Anticancer Research* 31:789-795, 2011.

17. Zhao, H., Lo, Y.-H., Ma, L., Waltz, S.E., Gray, J.K., Hung, M.-C., **Wang, S.-C.*** Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. *Molecular Cancer Therapeutics* 10:29-36, 2011.
18. Zhao, H., Lo, Y.-H., Yu, L. and **Wang, S.-C.*** Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-Oncogene in breast cancer. *Molecular Carcinogenesis* 50:383-389, 2011.
19. Zhao, H., Ou-Yang, F., Chen, I.-F., Hou, M.-F., Yuan, S.-S. F., Chang, H.-L., Lee, Y.-C., Plattner, R., Waltz, S., Ho, S.-M., Sims, J., and **Wang, S.-C.*** Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. *Neoplasia* 12:214-223, 2010.
20. **Wang, S.-C.** and Hung, M.-C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. *Clinical Cancer Research* 15: 6484-6489, 2009.
21. Nakagawa-Goto, K., Yamada, K., Nakamura, K., Chen, T.-H., Chiang, P.-C., Bastow, K. F., **Wang, S.-C.**, Spohn, B., Hung, M.-C., Lee, F.-Y., Lee F.-C., and Lee, K.-H.. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant - taxoid conjugates as novel cytotoxic agents. *Bioorganic & Medicinal Chemistry Letters* 17:5204-5209, 2007.
22. **Wang, S.-C.**, Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Li, L.-Y., Hawke, D. H., Kobayashi, R., Hung, M.-C. Tyrosine phosphorylation controls PCNA function through protein stability. *Nature Cell Biology* 8:1359-1368, 2006.
23. Yu, Z, Xia, W., Wang, H., **Wang, S.-C.**, Pan, Y., Kwong, K.Y., Hortobagyi, G.N. And Hung, M-C. Antitumor activity on an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. *Molecular Carcinogenesis* 45:667-675, 2006.
24. Xia, W.[‡], Lien, H.-C.[‡], **Wang, S.-C.**[‡], Pan, Y., Sahin, A., Kuo, Y.-H., Chang, K.-J., Zhou, X., Wang, H., Yu, Z., Hortobagyi, G., Shi, D.-R., and Hung, M.-C. ([‡], equally contributed) Expression of PEA3 and Lack of Correlation between PEA3 and HER-2/*neu* Expression in Breast Cancer. *Breast Cancer Research and Treatment* 98:295-301, 2006.
25. Chen, I-F., Ou-Yang, F., Hung, J-Y., Liu, J-C., Wang, H., **Wang, S.-C.**, Hou, M-F., Hortobagyi, G.N. and Hung, M-C. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. *Molecular Cancer Therapeutics* 5: 1-7, 2006.
26. **Wang, S.-C.** and Hung, M.-C. Cytoplasmic/nuclear shuttling and tumor progression. *Annals of the New York Academy of Sciences* 1059:1-5, 2005.
27. Giri, DK., Ali-Seyed, M., Li, L-Y., Lee, D-F., Ling, P., Bartholomeusz, G., **Wang, S.-C.** and Hung, M-C. Endosomal transport of ErbB-2: a mechanism for nuclear entry of cell surface receptor. *Molecular and Cellular Biology* 25:11005-11018, 2005. (PMCID1316946)
28. **Wang, S.-C.** and Hung, M.-C. Finding the bEST routes to cancer. *Cancer Biology & Therapy* 3(11):e132-e133, 2004.
29. **Wang, S.-C.**, Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Bartholomeusz, G., Ou-Yang, F., Giri, D.K., Hung, M.-C. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. *Cancer Cell* 6, 251-261, 2004.
30. Makino, K., Day, C.-P., **Wang, S.-C.**, Li, Y.M., Hung, M.-C. Upregulation of IKK α /IKK β by integrin-linked kinase is required for HER2/*neu*-induced NF- κ B antiapoptotic pathway. *Oncogene* 23:3883-3887, 2004.
31. Lee, C.M., Lo, H.-W., Shao, R.-P., **Wang, S.-C.**, Xia, W., Gershenson, D.M., Hung, M.-C. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. *Cancer Research* 64:1788-1793, 2004.
32. Yan, D.H., Wen, Y., Su, L.K., Xia, W., **Wang, S.C.**, Zhang, S., Gan, L., Lee, D.-F., Spohn B., Frey, J.A., Hortobagyi, G.N., Hung, M.C. A delayed chemically-induced tumorigenesis in *Bra2* mutant mice. *Oncogene* 23:1896-1901, 2004.
33. Lee, C.M., Shvartsman, H., Deavers, M.T., **Wang, S.-C.**, Xia, W., Schmandt, R., Bodurka, D. C., Atkinson, E.N., Malpica, A., Gershenson, D.M., Hung, M.-C., Lu, K.H. β -catenin nuclear localization is associated with grade in ovarian serous carcinoma. *Gynecology Oncology* 88:363-368, 2003.

34. Asada, S., Choi, Y., Yamada, M., **Wang, S.-C.**, Hung, M.-C., Qin, J., Uesugi, M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. *Proceedings of the National Academy of Science USA (PNAS)* 99:12747-12752, 2002.
35. **Wang, S.-C.**, Shao, R., Pao, A.Y., Zhang, S., Hung, M.-C., and Su, L.-K. Inhibition of cancer cell growth by BRCA2. *Cancer Research* 62:1311-1314, 2002.
36. **Wang, S.-C.** and Hung, M.-C. HER2 over-expression and cancer targeting. *Seminars in Oncology* 28(5)(Suppl. 16):115-124, 2001.
37. **Wang, S.-C.**, Zhang, L., Hortobagyi, G.N. and Hung, M.-C. Targeting HER-2: Recent developments and future directions for breast cancer patients. *Seminars in Oncology* 28(6)(Suppl. 18):21-29, 2001.
38. Zou, Y., Peng, H., Zhou, B., Wen, Y., Tsai, E.-M., **Wang, S.-C.**, and Hung M.-C. Systemic tumor suppression by the pro-apoptotic gene *bik* *Cancer Research* 62:8-12, 2001.
39. **Wang, S.-C.**, Makino, K., Su, L.-K., Pao, A.Y., Kim, J.S., Hung, M.-C. Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway. *Cancer Research* 61:2838-2842, 2001.
40. Tsai, E.-M.†, **Wang, S.-C.**†, Hung, M.-C. (†, equally contributed) Akt activation by estrogen in estrogen receptor-negative breast cancer cells. *Cancer Research* 61:8390-8392, 2001. (impact factor 8.650)
41. **Wang, S.-C.**, Makino, K., Xia, W., Kim, J.S., Im, S.-A., Peng, H., Mok, S.C., Singletary, S.E., Hung, M.-C. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. *Oncogene* 20:6960-6964, 2001.
42. Hung, M.-C. and **Wang, S.-C.** Suppressing HER-2/*neu*-mediated cell trans-formation by transcriptional repressors. *Breast Disease* 11:133-144, 2000.
43. **Wang, S.-C.** and Hung, M.-C. Transcriptional targeting of the HER-2/*neu* oncogene. *Drugs of Today* 36(12):835-843, 2000.
44. Xing, X.†, **Wang, S.-C.**†, Xia, W., Zou, Y., Shao, R., Kwong, K.-Y., Yu, Z., Zhang, S., Miller, S., Huang, L., Hung, M.-C. (†, equally contributed) The Ets protein PEA3 suppresses HER-2/*neu* overexpression and inhibits tumorigenesis. *Nature Medicine* 6:189-195, 2000.
45. Lo, S.-S., Lo, S.-H., **Wang, S.-C.**, Hung, M.-C. Inhibition of focal contact formation in cells transformed by p185^{neu}. *Molecular Carcinogenesis* 25:150-154, 1999.
46. Su, L.-K., **Wang, S.-C.**, Qi, Y., Luo, W., Hung, M.-C., Lin, S.-H. Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. *Oncogene* 17:2377-2381, 1998.
47. **Wang, S.-C.**, Lin, S.-H., Su, L.-K., Hung, M.-C. Changes in BRCA2 expression during progression of the cell cycle. *Biochem. Biophys. Res. Commun.*, 234:247-251, 1997.

C. BOOK CHAPTERS:

1. Hung, M.-C. and **Wang, S.-C.** Transcriptional repression in cancer gene therapy: targeting HER-2/*neu* overexpression as an example. *In: Gene Therapy and Molecular Biology*, Vol. 3 (pp. 1-11), Teni Boulikas (Ed.). Gene Therapy Press, Palo Alto, CA, 1998.
2. Hung, M.-C., **Wang, S.-C.**, and Hortobagyi, G. Targeting HER-2/*neu*-overexpressing cancer cells with transcriptional repressor genes delivered by cationic liposome. *In: Cancer Gene Therapy Using Cationic Liposome: Preclinic and Clinic Studies* (pp. 357-377), L. Huang, E. Wagner (Eds.). Academic Press, San Diego, CA, 1999.
3. Lo, H.-W., **Wang, S.-C.**, and Hung, M.-C. Chapter 38: Novel signaling pathways in breast cancer. *In: Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches* (pp. 823-839), Martine J. Piccart, Mien-Chie Hung, Lawrence J. Solin, Fatima Cardoso, William C. Wood (Eds.). Springer, 2006.

D. PATENT

U.S. Provisional Patent Application No. 62/204,684
 METHODS OF DIAGNOSING BREAST CANCER, MONITORING TREATMENT OF BREAST CANCER, AND TREATING BREAST CANCER

Inventor: Shao-Chun Wang